Загрузка...
Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network
Bevacizumab significantly extends progression-free survival (PFS) and overall survival (OS) times when combined with initial chemotherapy and continued as monotherapy until disease progression or unacceptable toxicity in patients with nonsquamous non-small cell lung cancer (NSCLC). In clinical pract...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AlphaMed Press
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228113/ https://ncbi.nlm.nih.gov/pubmed/21441299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0287 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|